Clinical-stage immuno-oncology company Portage Biotech pauses enrollment in ADPORT-601 trial and considers strategic alternatives.
Portage Biotech (NASDAQ: PRTG), a clinical-stage immuno-oncology company, is expanding its evaluation of strategic alternatives and pausing further enrollment in its ADPORT-601 clinical trial. The decision follows a review of the company's future funding needs for its adenosine antagonist platform and the current capital raising market. Portage will explore strategic alternatives, which may include partnering, asset sales, or mergers.
April 12, 2024
3 Articles